Global 23 Valent Pneumococcal Polysaccharide Vaccine Market is Projected to Reach Around USD 4212.53 Million By the End of 2030 with a Growing CAGR of 9.06% | Infinium Global Research

Infinium Global Research, a distinguished provider of market insights, introduces an exhaustive report unraveling the global and regional dynamics of the 23 Valent Pneumococcal Polysaccharide Vaccine Market. This comprehensive study delves into the market's segments, trends, forecasts, and dollar values, offering unparalleled insights for stakeholders in the pharmaceutical and healthcare sectors.

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/407

Market Insight:

The global 23 valent pneumococcal polysaccharide vaccine market, valued at USD 2,112.97 million in 2022, is poised to soar to USD 4,212.53 million by 2030, projecting a substantial CAGR of 9.06% during the forecast period from 2023 to 2030.

Market Dynamics:

The 23-valent pneumococcal polysaccharide vaccine stands as a pivotal preventive measure against severe pneumococcal diseases, covering 23 different strains of Streptococcus pneumonia bacteria. It plays a critical role in averting diseases like pneumonia, meningitis, and bloodstream infections. With a heightened emphasis on preventive healthcare and the expansion of vaccination programs globally, the market for this vaccine anticipates substantial growth. Market participants engaged in manufacturing and distributing this vaccine are poised for innovation and expansion opportunities.

Drivers and Growth Factors:

The market's growth is propelled by the surging geriatric population and government-driven immunization programs. The rise in global aging populations intensifies the need for vaccination against pneumococcal diseases, fostering considerable demand for the 23-valent vaccine. However, pricing issues in low-income regions impede accessibility. Conversely, the continuous expansion of vaccination programs presents a significant growth opportunity for the market.

Regional Market Insights:

North America is poised to dominate the 23 valent pneumococcal polysaccharide vaccine market, leveraging robust healthcare infrastructure, high awareness levels, and proactive government initiatives promoting immunization. Meanwhile, the Asia Pacific region emerges as the fastest-growing market due to increasing healthcare expenditure, heightened vaccination awareness, and a burgeoning elderly population.

Segmentation Insights:

The report dissects segments including type (pre-filled syringe, single dose vial), age group (2-10 years, 10-64 years, 64+ years), and distribution channels (hospitals, clinics, and others).

Key Players Profiled:

Profiles of industry frontrunners such as Merck & Co., Inc., GSK plc., and Sanofi, among others, are featured in the report, offering insights into their strategies and market positioning.

Enquire Here Get Customization & Check the Discount for the Report @ https://www.infiniumglobalresearch.com/market-reports/customization/407

Table of Content

Chapter 1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

Chapter 2. Executive Summary

2.1. 23 Valent Pneumococcal Polysaccharide Vaccine Market Highlights

2.2. 23 Valent Pneumococcal Polysaccharide Vaccine Market Projection

2.3. 23 Valent Pneumococcal Polysaccharide Vaccine Market Regional Highlights

Chapter 3. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter`s Five Forces Analysis

3.4. IGR-Growth Matrix Analysis

3.4.1. IGR-Growth Matrix Analysis by Type

3.4.2. IGR-Growth Matrix Analysis by Age Group

3.4.3. IGR-Growth Matrix Analysis by Distribution Channel

3.4.4. IGR-Growth Matrix Analysis by Region

3.5. Value Chain Analysis of 23 Valent Pneumococcal Polysaccharide Vaccine Market

Chapter 4. 23 Valent Pneumococcal Polysaccharide Vaccine Market Macro Indicator Analysis

Chapter 5. Company Profiles and Competitive Landscape

5.1. Competitive Landscape in the Global 23 Valent Pneumococcal Polysaccharide Vaccine Market

5.2. Companies Profiles

5.2.1. Merck & Co., Inc.

5.2.2. GSK plc.

5.2.3. Walvax Biotechnology Co., Ltd.

5.2.4. Zhi Fei Biological

5.2.5. SINOVAC

5.2.6. Chengdu Institute of Biology (CIB)

5.2.7. Sanofi

5.2.8. Pfizer Inc.

5.2.9. Beijing Minhai Biological Technology Co., Ltd.

5.2.10. Serum Institute of India Pvt. Ltd.

Chapter 6. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

6.1. Pre-filled Syringe

6.2. Single Dose Vial

Chapter 7. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

7.1. 2-10 Years

7.2. 10-64 Years

7.3. 64+ Years

Chapter 8. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

8.1. Hospitals

8.2. Clinics

8.3. Others

Chapter 9. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Region 2023-2030

9.1. North America

9.1.1. North America 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.1.2. North America 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.1.3. North America 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.1.4. North America 23 Valent Pneumococcal Polysaccharide Vaccine Market by Country

9.1.4.1. The U.S. 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.1.4.1.1. The U.S. 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.1.4.1.2. The U.S. 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.1.4.1.3. The U.S. 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.1.4.2. Canada 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.1.4.2.1. Canada 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.1.4.2.2. Canada 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.1.4.2.3. Canada 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.1.4.3. Mexico 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.1.4.3.1. Mexico 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.1.4.3.2. Mexico 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.1.4.3.3. Mexico 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.2. Europe

9.2.1. Europe 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.2.2. Europe 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.2.3. Europe 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.2.4. Europe 23 Valent Pneumococcal Polysaccharide Vaccine Market by Country

9.2.4.1. Germany 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.2.4.1.1. Germany 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.2.4.1.2. Germany 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.2.4.1.3. Germany 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.2.4.2. United Kingdom 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.2.4.2.1. United Kingdom 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.2.4.2.2. United Kingdom 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.2.4.2.3. United Kingdom 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.2.4.3. France 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.2.4.3.1. France 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.2.4.3.2. France 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.2.4.3.3. France 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.2.4.4. Italy 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.2.4.4.1. Italy 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.2.4.4.2. Italy 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.2.4.4.3. Italy 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.2.4.5. Rest of Europe 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.2.4.5.1. Rest of Europe 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.2.4.5.2. Rest of Europe 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.2.4.5.3. Rest of Europe 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.3. Asia Pacific

9.3.1. Asia Pacific 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.3.2. Asia Pacific 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.3.3. Asia Pacific 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.3.4. Asia Pacific 23 Valent Pneumococcal Polysaccharide Vaccine Market by Country

9.3.4.1. China 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.3.4.1.1. China 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.3.4.1.2. China 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.3.4.1.3. China 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.3.4.2. Japan 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.3.4.2.1. Japan 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.3.4.2.2. Japan 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.3.4.2.3. Japan 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.3.4.3. India 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.3.4.3.1. India 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.3.4.3.2. India 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.3.4.3.3. India 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.3.4.4. South Korea 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.3.4.4.1. South Korea 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.3.4.4.2. South Korea 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.3.4.4.3. South Korea 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.3.4.5. Australia 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.3.4.5.1. Australia 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.3.4.5.2. Australia 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.3.4.5.3. Australia 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.3.4.6. Rest of Asia-Pacific 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.3.4.6.1. Rest of Asia-Pacific 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.3.4.6.2. Rest of Asia-Pacific 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.3.4.6.3. Rest of Asia-Pacific 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.4. RoW

9.4.1. RoW 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.4.2. RoW 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.4.3. RoW 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.4.4. RoW 23 Valent Pneumococcal Polysaccharide Vaccine Market by Sub-region

9.4.4.1. Latin America 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.4.4.1.1. Latin America 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.4.4.1.2. Latin America 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.4.4.1.3. Latin America 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.4.4.2. Middle East 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.4.4.2.1. Middle East 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.4.4.2.2. Middle East 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.4.4.2.3. Middle East 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

9.4.4.3. Africa 23 Valent Pneumococcal Polysaccharide Vaccine Market

9.4.4.3.1. Africa 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type

9.4.4.3.2. Africa 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group

9.4.4.3.3. Africa 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel

More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/market-reports/enquiry/407

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of 23 valent pneumococcal polysaccharide vaccine.

=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2030.

=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand, and/or diversify.

2nd Floor, Ganadish Empire, Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027

About Infinium Global Research:

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes, and non-profit/non-government organizations to meet their knowledge and information needs.

Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations, and the environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

This release was published on openPR.